A Unique Iontophoretic Patch for Optimal Transdermal Delivery of Sumatriptan

Siegel, Steven J.; O'Neill, Christina; Dubé, Louise M.; Kaldeway, Peter; Morris, Russell; Jackson, David; Sebree, Terri

doi:10.1007/s11095-007-9317-1

Cited by 44 publications

(32 citation statements)

References 15 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transdermal delivery of sumatriptan may prove particularly helpful for migraineurs with gastric stasis (21)(22)(23). Whereas transdermal patches may have several limitations such as fluid leakage and increased skin irritation, likely from uneven contact to increased current density (24).…”

Section: Introductionmentioning

confidence: 99%

Preparation and Evaluation of Tubular Micelles of Pluronic Lecithin Organogel for Transdermal Delivery of Sumatriptan

et al. 2010

View full text Add to dashboard Cite

Abstract. The present work focuses on the preparation and evaluation of lecithin organogel system of thermoreversible polymer pluronic F127, which would enhance the stability and absorption of sumatriptan succinate across the skin. Formulations were developed with and without co-surfactant (pluronic F127). The prepared organogels were evaluated for its appearance, organoleptic characteristics, and feel upon application, homogeneity, occlusivenes, washability, pH, viscosity, spreadability, gel transition temperature of formulations. The formulations were also evaluated for drug content, in vitro drug diffusion properties and skin irritation testing. In vivo evaluation of formulations was carried out by hot plate and writhing test method, and finally the optimized formulation was subjected to stability studies. The developed formulations were easily washable, smooth in feel, and showed no clogging which indicate superior texture of system. Formulation, containing pluronic showed greater spreadability and higher drug diffusion rate as compared to pluronic free organogel. Drug content of organogel formulations was in the range of 94-97%. The pH of the formulations was 6.48±0.5 and 6.98±0.1, reflecting no risk of skin irritation. Pluronic not only enhances the stability of organogel by increasing the viscosity (from 6,541±234.76 to 7,826±155.65 poise) but also increases the release of drug from 67.39± 1.53% to 74.21±1.7%. The sumatriptan exhibits higher and long lasting antinociceptive effect as indicated by the persistent increase in reaction time in hot plate and inhibited abdominal contraction in acetic acid-induced writhing test (p<0.05). The prepared optimized formulation was found to be stable without any significant changes at room temperature.

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation and Evaluation of Tubular Micelles of Pluronic Lecithin Organogel for Transdermal Delivery of Sumatriptan

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Two studies have been done to investigate the pharmacokinetic features of the sumatriptan TDS [16,18,19]. The first study was conducted in eight healthy adults in order to evaluate the pharmacokinetic profile of four prototype sumatriptan patches in comparison to the subcutaneous sumatriptan injection (6 mg) and an oral tablet (50 mg) [18].…”

Section: Pharmacokineticsmentioning

confidence: 99%

Sumatriptan Iontophoretic Transdermal System for the Acute Treatment of Migraine

2014

View full text Add to dashboard Cite

SUMMARY We will describe the pharmacokinetic profile, clinical efficacy and safety data of the sumatriptan iontophoretic transdermal system (Zecuity®, NuPathe Inc., PA, USA), recently approved for the acute treatment of migraine with or without aura in adults, by the US FDA. This transdermal system utilizes a low-level electrical current to deliver sumatriptan transdermally and circumvents the GI tract. Pharmacokinetic studies have shown that iontophoretic delivery of sumatriptan achieves detectable plasma concentrations 15 min after activation with a maximum mean serum concentration of 22 ng/ml. A randomized, double-blind, controlled clinical trial demonstrated minimal triptan-related side effects and superior efficacy versus placebo. The pain-free rate at 2 h postdose was 18% of patients applying the sumatriptan patch versus 9% using the placebo (p = 0.0092). This sumatriptan transdermal system may be a good choice for migraineurs with severe nausea or vomiting, those with intolerable triptan-related adverse events and/or those not responding optimally to oral medications.

show abstract

“…A third prefilled iontophoretic system that has recently been approved by the FDA is Zecuity™ which is designed to deliver sumatriptan for the treatment of migraine [40]. The ideal therapeutic system to treat migraine would provide fast relief of symptoms and prevention of recurrence; hence, rapid onset and the ability to provide an on-demand bolus provide the rationale for the development of iontophoretic systems to treat migraine [41,42].…”

Section: Physical Enhancement Strategiesmentioning

confidence: 99%

Turning Theory into Practice: The Development of Modern Transdermal Drug Delivery Systems and Future Trends

Perumal

Murthy²

2013

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Despite its remarkable barrier function, the skin remains an attractive site for systemic drug delivery given its easy accessibility, large surface area and the possibility to bypass the gastrointestinal tract and the liver and so modify drug absorption kinetics. The pioneering work of Scheuplein, Higuchi and others in the 1960s helped to explain the processes involved in passive percutaneous absorption and led to the development of mathematical models to describe transdermal drug delivery. The intervening years have seen these theories turned to practice and a significant number of transdermal systems are now available including some that employ active drug delivery. This review briefly discusses the evolution of transdermal therapeutic systems over the years and the potential of newer transdermal technologies to deliver hydrophilic drugs and macromolecules through the skin.

show abstract

A Unique Iontophoretic Patch for Optimal Transdermal Delivery of Sumatriptan

Abstract: This study met the initial objective to define the dose-current relationship in humans as well as delimiting specific current and current density targets for a well tolerated patch design that can deliver therapeutic drug levels for longer periods than currently possible.

Cited by 44 publications

References 15 publications

Preparation and Evaluation of Tubular Micelles of Pluronic Lecithin Organogel for Transdermal Delivery of Sumatriptan

Preparation and Evaluation of Tubular Micelles of Pluronic Lecithin Organogel for Transdermal Delivery of Sumatriptan

Sumatriptan Iontophoretic Transdermal System for the Acute Treatment of Migraine

Turning Theory into Practice: The Development of Modern Transdermal Drug Delivery Systems and Future Trends

Contact Info

Product

Resources

About